Juno Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
104
About the Report
About the Report
Summary
Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. It develops CD19 CAR and WT-1 TCR clinical programs which include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno offers CAR and TCR product candidates targeting multiple cancer types. The company is evaluating its pipeline candidates for the treatment of relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL), r/r B-Cell Non-Hodgkin's Lymphoma (NHL); r/r Acute Lymphoid Leukemia (ALL). It works in collaboration with various cancer centers. Juno is headquartered in Seattle, Washington, the US.
Juno Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
JW Therapeutics Raises USD90 Million in Series A Financing 16
AbViro Raises USD0.4 Million in Venture Financing 17
Juno Therapeutics Raises USD134 Million in Series B Financing 18
Juno Therapeutics Raises USD 31 Million In Extended Series A Financing 19
Juno Therapeutics Raises USD 145 Million In Series A Financing 20
AbVitro Raises USD 0.75 Million In Venture Financing 22
AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 23
X-BODY Raises Additional USD 0.6 Million In Venture Financing 24
Partnerships 25
Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 25
Juno Therapeutics Forms Joint Venture with WuXi AppTec 26
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 27
Celgene Exercises Option Agreement with Juno Therapeutics 28
Juno Therapeutics Enters into Research Agreement with Editas Medicine 29
MedImmune Enters into Agreement with Juno Therapeutics 30
Juno Therapeutics Enters into Research Agreement with FHCRC 31
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 32
Licensing Agreements 33
Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 33
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 34
Juno Therapeutics Enters into Licensing Agreement with Oncotracker 35
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 36
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 37
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 38
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 39
Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 41
Vernalis Enters into Licensing Agreement with RedoxTherapies 42
Juno Therapeutics Enters into Licensing Agreement with St. Jude Children's Research Hospital 43
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 44
Juno Therapeutics Enters into Licensing Agreement with FHCRC 45
Juno Therapeutics Enters into Licensing Agreement with Trianni 46
Celgene Enters into Licensing Agreement with Juno Therapeutics 47
Equity Offering 48
Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 48
Juno Therapeutics Raises USD304 Million in IPO 50
Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 52
Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 53
Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 54
Asset Transactions 55
Roche Acquires PETE Technology from AbVitro 55
Acquisition 56
Celgene Acquires Juno Therapeutics for USD9 Billion 56
Juno Therapeutics Acquires RedoxTherapies 58
Juno Therapeutics Acquires AbVitro 59
Juno Therapeutics Acquires X-BODY 60
AstraZeneca May Acquire Juno Therapeutics 61
Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 62
Juno Therapeutics Acquires ZetaRx BioSciences 63
Juno Therapeutics Inc-Key Competitors 64
Juno Therapeutics Inc-Key Employees 65
Juno Therapeutics Inc-Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Joint Venture 66
Recent Developments 67
Strategy And Business Planning 67
Sep 21, 2017: Juno Therapeutics Opens New Headquarters and Research Center 67
Financial Announcements 68
Nov 01, 2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results 68
Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results 71
May 04, 2017: Juno Therapeutics Reports First Quarter 2017 Financial Results 73
Mar 01, 2017: Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results 75
Corporate Communications 79
Jan 05, 2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer 79
Nov 27, 2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO 80
May 23, 2017: Juno Therapeutics Appoints Jay Flatley to Board of Directors 81
Apr 19, 2017: Juno Therapeutics Appoints Rupert Vessey to Board of Directors 82
Apr 17, 2017: Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development 83
Jan 27, 2017: Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations 84
Legal and Regulatory 85
Jan 12, 2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc.-JUNO 85
Government and Public Interest 86
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 86
Product News 87
12/12/2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH 87
12/09/2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL 89
11/01/2017: Juno Therapeutics to Highlight New Advances of Anti-Neoplastic Drug Candidate JCARH125 at ASH Conference 90
Oct 11, 2017: New insights into CAR T-cell therapy's potential side effects 92
06/05/2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma 94
Clinical Trials 96
Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma 96
Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference 98
Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma 100
May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting 102
May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy 103
Appendix 104
Methodology 104
About GlobalData 104
Contact Us 104
Disclaimer 104
List of Figure
List of Figures
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
JW Therapeutics Raises USD90 Million in Series A Financing 16
AbViro Raises USD0.4 Million in Venture Financing 17
Juno Therapeutics Raises USD134 Million in Series B Financing 18
Juno Therapeutics Raises USD 31 Million In Extended Series A Financing 19
Juno Therapeutics Raises USD 145 Million In Series A Financing 20
AbVitro Raises USD 0.75 Million In Venture Financing 22
AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 23
X-BODY Raises Additional USD 0.6 Million In Venture Financing 24
Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 25
Juno Therapeutics Forms Joint Venture with WuXi AppTec 26
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 27
Celgene Exercises Option Agreement with Juno Therapeutics 28
Juno Therapeutics Enters into Research Agreement with Editas Medicine 29
MedImmune Enters into Agreement with Juno Therapeutics 30
Juno Therapeutics Enters into Research Agreement with FHCRC 31
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 32
Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 33
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 34
Juno Therapeutics Enters into Licensing Agreement with Oncotracker 35
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 36
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 37
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 38
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 39
Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 41
Vernalis Enters into Licensing Agreement with RedoxTherapies 42
Juno Therapeutics Enters into Licensing Agreement with St. Jude Children's Research Hospital 43
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 44
Juno Therapeutics Enters into Licensing Agreement with FHCRC 45
Juno Therapeutics Enters into Licensing Agreement with Trianni 46
Celgene Enters into Licensing Agreement with Juno Therapeutics 47
Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 48
Juno Therapeutics Raises USD304 Million in IPO 50
Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 52
Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 53
Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 54
Roche Acquires PETE Technology from AbVitro 55
Celgene Acquires Juno Therapeutics for USD9 Billion 56
Juno Therapeutics Acquires RedoxTherapies 58
Juno Therapeutics Acquires AbVitro 59
Juno Therapeutics Acquires X-BODY 60
AstraZeneca May Acquire Juno Therapeutics 61
Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 62
Juno Therapeutics Acquires ZetaRx BioSciences 63
Juno Therapeutics Inc, Key Competitors 64
Juno Therapeutics Inc, Key Employees 65
Juno Therapeutics Inc, Subsidiaries 66
Juno Therapeutics Inc, Joint Venture 66
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.